Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Liabilities and Shareholders Equity (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 3.92% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 23.05% year-over-year, with the annual reading at $1.3 million for FY2025, 3.92% down from the prior year.
  • Liabilities and Shareholders Equity hit $1.3 million in Q4 2025 for Guided Therapeutics, up from $903000.0 in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.9 million in Q3 2022 to a low of $903000.0 in Q3 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $1.9 million across 5 years, with a median of $1.7 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 548.9% in 2021 and later plummeted 51.51% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $2.0 million in 2021, then soared by 65.0% to $3.4 million in 2022, then crashed by 50.42% to $1.7 million in 2023, then decreased by 17.44% to $1.4 million in 2024, then dropped by 3.92% to $1.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for GTHP at $1.3 million in Q4 2025, $903000.0 in Q3 2025, and $940000.0 in Q2 2025.